SAN DIEGO, Feb. 4, 2014 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio" or the "Company") (Nasdaq:APRI) (http://www.apricusbio.com), today announced that Richard Pascoe, Chief Executive Officer, will present at the 16th Annual BIO CEO & Investor Conference, being held at The Waldorf Astoria in New York City. Mr. Pascoe's presentation will take place on Tuesday, February 11, 2014 at 9:30 a.m. Eastern Time.
The presentation will be webcast and accessible to the public online at http://www.veracast.com/webcasts/bio/ceoinvestor2014/18225148879.cfm or via the Company's website at http://www.apricusbio.com. A replay will be available for 90 days after the presentation.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a pharmaceutical company that develops and markets through its licensing partners innovative treatments that have the potential to help large patient populations across numerous, large-market therapeutic classes including male and female sexual health. The Company has one approved product, Vitaros®, for the treatment of erectile dysfunction, which is now approved in Europe and Canada and will be commercialized by Apricus' marketing partners, which include Abbott Laboratories Limited, Takeda Pharmaceuticals International GmbH, Hexal AG (Sandoz), Bracco SpA and Laboratoires Majorelle. Femprox®, the Company's product candidate for the treatment of female sexual interest/arousal disorder, has successfully completed a nearly 400-subject proof-of-concept study.
For further information on Apricus, visit http://www.apricusbio.com.